Exact Sciences Acquires Thrive Earlier Detection
October 27, 2020
Exact Sciences Corp. agreed to acquire Thrive Earlier Detection Corp. for up to $2.15 billion in cash and stock, a deal intended to combine Thrive's CancerSEEK multi-cancer blood test with Exact Sciences' commercial and R&D capabilities. The transaction, unanimously approved by both boards, is designed to accelerate development, regulatory approval, and adoption of blood-based multi-cancer screening.
- Buyers
- Exact Sciences Corp.
- Targets
- Thrive Earlier Detection Corp.
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Abbott Laboratories Acquires Exact Sciences for $21 Billion
November 20, 2025
Healthcare Services
Abbott Laboratories agreed to acquire Exact Sciences Corporation for approximately $21 billion, with Exact Sciences shareholders receiving $105 per share in cash. The deal is expected to close in the second quarter of 2026, and Exact Sciences will operate as a subsidiary of Abbott after completion.
-
Sherlock Biosciences Acquires Sense Biodetection
February 1, 2023
Biotechnology
Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.
-
Tesis Biosciences Acquires Genome Explorations
February 16, 2022
Biotechnology
Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.
-
Exact Sciences Acquires PreventionGenetics
January 9, 2022
Healthcare Services
Exact Sciences Corp. acquired PreventionGenetics, a CLIA- and ISO-accredited genetic testing laboratory based in Marshfield, Wisconsin, for $190 million (50% stock, 50% cash) to accelerate its entrance into hereditary cancer testing. PreventionGenetics reported preliminary 2021 revenue of about $36 million and ~100+ staff; Exact Sciences intends to leverage its commercial reach to expand hereditary cancer and genetic testing domestically and internationally.
-
Veracyte Acquires Decipher Biosciences
February 3, 2021
Biotechnology
Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.
-
Exact Sciences Acquires Paradigm Diagnostics and Viomics
March 3, 2020
Healthcare Services
Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.